2022-500681-98-00已完成1 期
A randomized first-in-human, Phase 1, single-center, observer-blind, active-controlled 3-arm study to evaluate the safety, tolerability, and immunogenicity of one single administration of TETRALITE, a novel adjuvanted influenza vaccine, in healthy participants aged 18 to 50 years
Litevax B.V.1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2022年8月3日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 60
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Luuk Hilgers
Scientific
Litevax B.V.
研究点 (1)
Loading locations...
相似试验
尚未招募
不适用
A phase 1 clinical trial to evaluate safety, tolerability, pharmacokinetic properties and effectiveness after applying an investigational cream to healthy adults and atopic dermatitis patientsDiseases of the skin and subcutaneous tissueKCT0005182Avixgen24
已完成
1 期
A first-in-human, randomized, double-blind, placebo-controlled, single ascending dose and multiple ascending dose (SAD/MAD) study of ENN0403 in healthy subjectsDiabetic retinopathyonalcoholic steatohepatitis (NASH)Nonalcoholic steatohepatitis (NASH)Inflammatory and Immune System - Other inflammatory or immune system disordersPulmonary fibrosisACTRN12622001067763EnnovaBio Australia Pharmaceuticals Pty Ltd69
撤回
不适用
A phase 1, first-in-human, 2-part, randomized, double-blind, placebo controlled, single ascending dose and sequential, open-label, multiple ascending dose study to evaluate the safety, tolerability, pharmacodynamics, and pharmacokinetics of VIS171 in healthy participants and participants with autoimmune disease(s)autoimmune hepatitisautoimmune disease(s)1001965410003816AIHNL-OMON51485Parexel Nederland3
已完成
不适用
A phase I, single-centre, randomised, single-blinded, placebo-controlled single ascending dose study, followed by an open-label extension, evaluating the safety, pharmacokinetics, pharmacodynamics and efficacy of ALX 0651, administered intravenously to healthy male volunteers.NL-OMON35929Ablynx NV76
尚未招募
1 期
A Study of the Pharmacokinetics and Safety of a Single Dose of Lenabasum in Subjects with Hepatic Impairment Compared with Matched Healthy ControlsACTRN12620000712909Corbus Pharmaceuticals Inc32